Prostate Cancer Clinical Trials in Philadelphia, Pennsylvania

20 studies are recruiting for prostate cancer in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Perelman Center for Advanced Medicine ( Site 0067), Philadelphia, Pennsylvania
    Locations
    298 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06925737 on ClinicalTrials.gov

  2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  3. Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

    This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the …

    Stage
    Not phased
    Ages
    18 and older
    Site
    Fox Chase Cancer Center, Philadelphia, Pennsylvania
    Locations
    8 in total
    Run by
    Varian, a Siemens Healthineers Company

    See if you can join NCT05804318 on ClinicalTrials.gov

  4. DESTINY-PANTUMOUR04

    This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

    Stage
    Not phased
    Ages
    18 to 130
    Site
    Research Site, Philadelphia, Pennsylvania
    Locations
    18 in total
    Run by
    AstraZeneca

    See if you can join NCT07124000 on ClinicalTrials.gov

  5. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 a…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Thomas Jefferson University, Philadelphia, Pennsylvania
    Locations
    57 in total
    Run by
    Amgen

    See if you can join NCT04221542 on ClinicalTrials.gov

  6. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania
    Locations
    33 in total
    Run by
    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

  7. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    Thomas Jefferson University Honickman Center, Philadelphia, Pennsylvania
    Locations
    36 in total
    Run by
    Janux Therapeutics

    See if you can join NCT05519449 on ClinicalTrials.gov

  8. Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

    The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility a…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Thomas Jefferson University, Philadelphia, Pennsylvania
    Locations
    9 in total
    Run by
    Amgen

    See if you can join NCT06613100 on ClinicalTrials.gov

  9. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Investigative Site #109, Philadelphia, Pennsylvania
    Locations
    18 in total
    Run by
    MOMA Therapeutics

    See if you can join NCT06545942 on ClinicalTrials.gov

  10. PSMA PET Combined With MRI for the Detection of PCa

    This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    MidLantic Urology, Philadelphia, Pennsylvania
    Locations
    18 in total
    Run by
    Telix Pharmaceuticals (Innovations) Pty Limited

    See if you can join NCT07052214 on ClinicalTrials.gov

  11. A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

    The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
    Locations
    12 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06457919 on ClinicalTrials.gov

  12. TERPS Trial for de Novo Oligometastic Prostate Cancer

    This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia, Pennsylvania
    Locations
    10 in total
    Run by
    University of Maryland, Baltimore

    See if you can join NCT05223803 on ClinicalTrials.gov

  13. Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

    This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy. Treatment of interest: the investigational tre…

    Stage
    Phase 2
    Ages
    18 to 100
    Site
    Fox Chase Cancer Center, Philadelphia, Pennsylvania
    Locations
    81 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT06780670 on ClinicalTrials.gov

  14. International Registry for Men With Advanced Prostate Cancer (IRONMAN)

    Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry an…

    Stage
    Not phased
    Ages
    21 and older
    Site
    Fox Chase Cancer Center - Temple Health, Philadelphia, Pennsylvania
    Locations
    121 in total
    Run by
    Prostate Cancer Clinical Trials Consortium

    See if you can join NCT03151629 on ClinicalTrials.gov

  15. Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

    This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic pros…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania
    Locations
    20 in total
    Run by
    VA Office of Research and Development

    See if you can join NCT04787744 on ClinicalTrials.gov

  16. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  17. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  18. Hypofractionated WPPT With HDR Boost

    This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Pennsylvania, Philadelphia, Pennsylvania
    Run by
    Abramson Cancer Center at Penn Medicine

    See if you can join NCT06591819 on ClinicalTrials.gov

  19. Prostate Tissue BioBank

    Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1/2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13. The investigators have shown that 5% of men diagnosed with prostate cancer loca…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Pennsylvania, Philadelphia, Pennsylvania
    Run by
    Abramson Cancer Center at Penn Medicine

    See if you can join NCT06659614 on ClinicalTrials.gov

  20. The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study

    The overarching goal of this trial is to develop mechanisms to improve cardiovascular care among such prostate cancer patients receiving ADT by increasing patient awareness of individualized cardiovascular risk estimates and mitigation opportunities. Patients will be given access to a web-based qua…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
    Run by
    Vivek Narayan

    See if you can join NCT06064149 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.